AKTX — Akari Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Akari Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.4 | -17.7 | -10 | -19.8 | -17.3 |
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.557 | -4.58 | -5.56 | 0.686 | 8.22 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.98 | 0.822 | -0.866 | 6.54 | -0.404 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -18.8 | -21.5 | -16.4 | -12.6 | -10.6 |
| Other Investing Cash Flow Items | — | — | — | 0.382 | — |
| Sale of Business | |||||
| Cash from Investing Activities | — | — | — | 0.382 | — |
| Financing Cash Flow Items | — | — | — | -1.1 | -0.499 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.3 | 25.3 | 7.02 | 11 | 13.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.69 | 3.89 | -9.4 | -1.19 | 2.6 |